Information Provided By: 
Fly News Breaks for April 17, 2019
RARE
Apr 17, 2019 | 18:13 EDT
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $75 price target after its Analyst Day presentations which "highlighted meaningful updates across the board for clinical assets as well as early- and late-stage programs currently in development." The analyst says he continues to recommend the stock given the "number of near-term catalysts on the horizon" along with "three additional programs expected to enter the clinic in 2020."
News For RARE From the Last 2 Days
